Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Rodeo Therapeutics is raising $8,950,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Thong Le played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rodeo Therapeutics

Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.

To learn more about Rodeo Therapeutics, visit http://rodeotherapeutics.com/

Contact:
Thong Le, President and Chief Executive Officer
206-957-7300

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved